Anbogen Therapeutics (ABT) is a clinical stage biopharmaceutical company founded in 2019, based in Taipei, Taiwan and focused on developing first/best-in-class precision oncology medicines. We target cancer patients having driver gene mutations with the greatest unmet therapeutic needs. Founders and the executive team deeply rooted in science and with extensive experience in medicinal chemistry, drug discovery and clinical development.